The results of an in-development drug trial seem to mark a victory for one side of the long-running debate over what causes Alzheimer’s disease. At the center of the debate: the amyloid hypothesis, which suggests that Alzheimer’s disease is due to the accumulation of sticky amyloid plaques in the brain. The highest dose tested of Biogen and Eisai’s drug, BAN2401, had a dramatic effect on amyloid buildup in the brain. But some skeptics aren't convinced — and say it's impossible to draw conclusions from the study.
Learn more: Alzheimer’s study sparks a new round of debate over the amyloid hypothesis